Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National breast cancer study of epirubicin plus CMF versus classical CMF adjuvant therapy
ISRCTN42625759Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Apr 1996
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide, methotrexate and fluorouracil in breast cancer (2 arms), sponsored by University of Birmingham. Primary endpoints: 5-year disease-free survival and 5-year overall survival. Started Apr 1996; status: completed.
02
Drugs
epirubicincyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN42625759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42625759.